<DOC>
	<DOCNO>NCT02509624</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( PK ) , safety , tolerability GS-4997 adult impair hepatic function relative match , healthy control . Each participant control group match participant impaired hepatic function age ( ± 10 year ) , gender , body mass index ( ± 20 % ) .</brief_summary>
	<brief_title>Pharmacokinetics GS-4997 Adults With Normal Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>All individual : Body mass index ( BMI ) 18 40 kg/m^2 , inclusive Creatinine clearance ( CrCl ) ≥ 60 mL/min ( use CockcroftGault method ) base serum creatinine body weight Individuals impair hepatic function : Aside hepatic insufficiency , must sufficiently healthy study participation base upon screen evaluation . Must diagnosis chronic ( &gt; 6 month ) , stable hepatic impairment clinically significant change hepatic status within 3 month ( 90 day ) prior study drug administration ( Day 1 ) . Individuals severe hepatic impairment must score ChildPughTurcotte scale 1015 screening . Individuals moderate hepatic impairment must score ChildPughTurcotte scale 79 screening . Individuals mild hepatic impairment must score ChildPughTurcotte scale 56 screening . Healthy individual ( match control ) : Must good health base upon screen evaluation . All individual : Pregnant lactate female Have receive investigational compound device within 30 day prior study dose Current alcohol substance abuse A positive test result human immunodeficiency virus ( HIV1/2 ) antibody Have poor venous access limit phlebotomy Have treat systemic steroid , antiHIV agent , immunosuppressant therapy , chemotherapeutic agent within 3 month prior screen expect receive agent study ( eg , corticosteroid , immunoglobulin , immune cytokinebased therapy ) would contraindicate exclusion criterion . Significant serious skin disease , limited rash , food allergy , eczema , psoriasis , urticaria Significant drug sensitivity drug allergy ( anaphylaxis hepatoxicity ) Unstable cardiac disease , include history myocardial infarction within 1 year screening , recurrent episode ventricular tachycardia despite appropriate medical therapy , decompensated congestive heart failure , dilate cardiomyopathy leave ventricular ejection fraction &lt; 40 % ) , family history Long QT Syndrome , unexplained death otherwise healthy individual age 1 30 year . Syncope , palpitation , unexplained dizziness Implanted defibrillator pacemaker . Severe peptic ulcer disease , severe gastroesophageal reflux disease , severe gastric acid hypersecretory condition . Medical surgical treatment permanently alter gastric absorption ( eg , gastric intestinal surgery ) . A history cholecystectomy exclusionary . History prior allogeneic bone marrow progenitor cell solid organ transplantation . Currently register organ transplantation list . History bleed esophageal varix within 90 day prior Admission ( Day 1 ) . Use strong CYP3A4 inhibitor ( eg , indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketoconazole , nefazodone , saquinavir , suboxone , telithromycin , atazanavir ) strong CYP3A4 inducer ( eg , carbamazepine , rifampin , phenytoin St. John 's wort ) , within 28 day prior study drug administration ( Day 1 ) . Consumption grapefruit juice , grapefruit , Seville orange juice within 2 week prior study drug administration ( Day 1 ) . Recent significant change use nicotine nicotine containing product Individuals impair hepatic function : Aside hepatic insufficiency , serious active medical psychiatric illness , opinion investigator , would interfere treatment , assessment , compliance protocol . Chronic hepatitis B virus ( HBV ) infection , define positive test hepatitis B surface antigen ( HBsAg ) , unless patient treat nucleos ( ) ide analog ( eg , tenofovir entecavir ) least 6 month HBV DNA polymerase chain reaction ( PCR ) assay persistently undetectable least 6 month . Positive test drug abuse , include alcohol screen Day 1/checkin , exception opioids tetrahydrocannabinol ( THC , marijuana ) prescription investigator verification pain management . Individuals screen positive benzodiazepine may allow prescribed care physician review investigator Sponsor . Requires paracentesis &gt; 1 time per month . Individuals hepatic impairment comorbid disease associate hepatic impairment require medication ( ) must take medication ( ) without change dose &gt; 3 month prior screen . Changes concomitant medication dosage use treat symptom hepatic impairment associate comorbid condition could lead clinically significant change medical condition course study would affect ability interpret potential drugdrug interaction within 28 day prior dose . Healthy individual ( match control ) : A positive test result hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( antiHBc ) Positive test drug abuse , include alcohol screen Day 1/checkin . Have serious active medical psychiatric illness ( include depression ) , opinion investigator , would interfere treatment , assessment , compliance protocol . History liver disease . Have take prescription medication overthecounter medication include herbal product within 28 day commence study drug dose exception vitamin , acetaminophen , ibuprofen , hormonal contraceptive medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>